Literature DB >> 15117285

Novel antipsychotics in bipolar and schizoaffective mania.

G J R Mensink1, C J Slooff.   

Abstract

OBJECTIVE: Novel antipsychotics are increasingly used in the treatment of bipolar and schizoaffective mania. This paper presents an overview of the controlled studies in this field.
METHOD: Using cross-references, a computerized search was performed on MEDLINE and EMBASE psychiatry covering the period 1990-2002.
RESULTS: Olanzapine and risperidone, added to mood stabilizers, and olanzapine as monotherapy enjoy the most evidential support in terms of efficacy and side-effect profile for their use in acute bipolar mania. The use of modern antipsychotics in bipolar prophylaxis and in both the short- and long-term treatment of schizomania has not been widely studied yet.
CONCLUSION: More controlled trials are still needed comparing modern antipsychotics as monotherapy and adjunctive to mood stabilizers with conventional antipsychotics, lithium, anticonvulsants and with each other in short-term and, especially, maintenance treatment of (schizo)mania. Partly based on controlled studies, olanzapine, risperidone and other modern antipsychotics could become preferable for these indications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15117285     DOI: 10.1111/j.1600-0047.2004.00295.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  6 in total

1.  Conceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERI-BD.

Authors:  Robert C Young; Herbert C Schulberg; Ariel G Gildengers; Martha Sajatovic; Benoit H Mulsant; Laszlo Gyulai; John Beyer; Lauren Marangell; Mark Kunik; Thomas Ten Have; Martha L Bruce; Ruben Gur; Patricia Marino; Jovier D Evans; Charles F Reynolds; George S Alexopoulos
Journal:  Bipolar Disord       Date:  2010-02       Impact factor: 6.744

2.  Predictive factors for time to remission and recurrence in patients treated for acute mania: health outcomes of manic episodes (HOME) study.

Authors:  Kaan Kora; Mete Saylan; Cengiz Akkaya; Nesrin Karamustafalioglu; Nesrin Tomruk; Aziz Yasan; Timucin Oral
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

3.  Prescription patterns of psychotropic medications in elderly compared with younger participants who achieved a "recovered" status in the systematic treatment enhancement program for bipolar disorder.

Authors:  Rayan K Al Jurdi; Lauren B Marangell; Nancy J Petersen; Melissa Martinez; Laszlo Gyulai; Martha Sajatovic
Journal:  Am J Geriatr Psychiatry       Date:  2008-11       Impact factor: 4.105

4.  Risperidone-induced mania: An emergent complication of treatment.

Authors:  Anjana Rao Kavoor; Sayantanava Mitra; Supriya Kumar Mondal; Basudeb Das
Journal:  J Pharmacol Pharmacother       Date:  2014-10

Review 5.  The Therapeutic Potential of Carnosine as an Antidote against Drug-Induced Cardiotoxicity and Neurotoxicity: Focus on Nrf2 Pathway.

Authors:  Giuseppe Caruso; Anna Privitera; Barbara Moura Antunes; Giuseppe Lazzarino; Susan Marie Lunte; Giancarlo Aldini; Filippo Caraci
Journal:  Molecules       Date:  2022-07-12       Impact factor: 4.927

Review 6.  Neurotoxicity and nephrotoxicity caused by combined use of lithium and risperidone: a case report and literature review.

Authors:  Chih-Wei Hsu; Yu Lee; Chun-Yi Lee; Pao-Yen Lin
Journal:  BMC Pharmacol Toxicol       Date:  2016-12-14       Impact factor: 2.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.